Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 8.35 Billion KRW | -5.18% |
| 2022 | 8.8 Billion KRW | 83.43% |
| 2021 | 4.8 Billion KRW | 115.56% |
| 2020 | -30.86 Billion KRW | -7.14% |
| 2019 | -28.8 Billion KRW | -225.35% |
| 2018 | 22.98 Billion KRW | 1005.79% |
| 2017 | -2.53 Billion KRW | 65.77% |
| 2016 | -7.41 Billion KRW | -54.61% |
| 2015 | -4.79 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.3 Billion KRW | -115.66% |
| 2024 Q2 | -1.57 Billion KRW | -20.48% |
| 2023 Q2 | 6.13 Billion KRW | -42.4% |
| 2023 Q4 | 8.35 Billion KRW | 15.04% |
| 2023 FY | 8.35 Billion KRW | -5.18% |
| 2023 Q1 | 10.65 Billion KRW | 21.0% |
| 2023 Q3 | 7.25 Billion KRW | 18.25% |
| 2022 FY | 8.8 Billion KRW | 83.43% |
| 2022 Q4 | 8.8 Billion KRW | 369.2% |
| 2022 Q3 | -3.27 Billion KRW | 73.26% |
| 2022 Q1 | -16.9 Billion KRW | -451.94% |
| 2022 Q2 | -12.23 Billion KRW | 27.61% |
| 2021 Q4 | 4.8 Billion KRW | 284.6% |
| 2021 FY | 4.8 Billion KRW | 115.56% |
| 2021 Q3 | -2.6 Billion KRW | -134.38% |
| 2021 Q1 | -31.93 Billion KRW | -4226.15% |
| 2021 Q2 | 7.56 Billion KRW | 123.69% |
| 2020 Q2 | -31.44 Billion KRW | -11.79% |
| 2020 Q3 | -34.2 Billion KRW | -8.78% |
| 2020 Q4 | 774.02 Million KRW | 102.26% |
| 2020 FY | -30.86 Billion KRW | -7.14% |
| 2020 Q1 | -28.13 Billion KRW | 16.59% |
| 2019 Q3 | -15.53 Billion KRW | -232.61% |
| 2019 Q2 | 11.71 Billion KRW | -55.88% |
| 2019 Q1 | 26.54 Billion KRW | 109.82% |
| 2019 FY | -28.8 Billion KRW | -225.35% |
| 2019 Q4 | -33.72 Billion KRW | -117.17% |
| 2018 Q3 | 34.41 Billion KRW | 93.54% |
| 2018 Q4 | 12.65 Billion KRW | -63.24% |
| 2018 FY | 22.98 Billion KRW | 1005.79% |
| 2018 Q1 | 4.37 Billion KRW | 272.42% |
| 2018 Q2 | 17.77 Billion KRW | 306.45% |
| 2017 Q3 | 3.49 Billion KRW | 148.05% |
| 2017 Q1 | -7.24 Billion KRW | -8.28% |
| 2017 Q2 | -7.27 Billion KRW | -0.41% |
| 2017 Q4 | -2.53 Billion KRW | -172.58% |
| 2017 FY | -2.53 Billion KRW | 65.77% |
| 2016 FY | -7.41 Billion KRW | -54.61% |
| 2016 Q1 | -7.11 Billion KRW | -48.37% |
| 2016 Q2 | -15.8 Billion KRW | -122.29% |
| 2016 Q4 | -6.69 Billion KRW | 53.95% |
| 2016 Q3 | -14.52 Billion KRW | 8.1% |
| 2015 Q4 | -4.79 Billion KRW | 0.0% |
| 2015 FY | -4.79 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 118.084% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 120.579% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 81.583% |
| Bioneer Corporation | -3.9 Billion KRW | 313.722% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 43.624% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 7.119% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 134.193% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 97.853% |
| Medy-Tox Inc. | 49.58 Billion KRW | 83.156% |
| Peptron, Inc. | 4.86 Billion KRW | -71.543% |
| Amicogen, Inc. | 125.26 Billion KRW | 93.333% |
| Genexine, Inc. | 61.39 Billion KRW | 86.397% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 161.021% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 114.9% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 84.41% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 125.356% |
| SillaJen, Inc. | -13.89 Billion KRW | 160.121% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 90.09% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 69.491% |
| Genomictree Inc. | -43.43 Billion KRW | 119.228% |
| MedPacto, Inc. | -64 Billion KRW | 113.05% |
| D&D Pharmatech | -7.5 Billion KRW | 211.241% |
| EASY BIO,Inc. | 53.21 Billion KRW | 84.304% |
| GI Innovation, Inc. | -4.82 Billion KRW | 273.184% |